Oncologist

雜志介紹

Oncologist雜志介紹

《Oncologist》是一本以English為主的未開放獲取國際優秀期刊，中文名稱腫瘤學家，本刊主要出版、報道醫學-ONCOLOGY領域的研究動態以及在該領域取得的各方面的經驗和科研成果，介紹該領域有關本專業的最新進展，探討行業發展的思路和方法，以促進學術信息交流，提高行業發展。該刊已被國際權威數據庫SCIE收錄，為該領域相關學科的發展起到了良好的推動作用，也得到了本專業人員的廣泛認可。該刊最新影響因子為4.8，最新CiteScore 指數為10.4。

本刊近期中國學者發表的論文主要有：

• Association Between Lymphopenia and Survival Outcomes in Esophageal Carcinoma Patients Receiving Combined Immunotherapy and Chemoradiotherapy

  Author: Cheng, Xingyuan; Chen, Baoqing; Wang, Sifen; Zhang, Jun; Zhu, Jinhan; Liu, Mengzhong; Liu, Shiliang; Xi, Mian

• Radiotherapy Plus Temozolomide With or Without Nimotuzumab Against the Newly Diagnosed EGFR-Positive Glioblastoma: A Retrospective Cohort Study

  Author: She, Lei; Gong, Xuan; Su, Lin; Liu, Chao

• Adjuvant Abemaciclib Combined with Endocrine Therapy: Efficacy Results in monarchE Cohort 1

  Author: Toi, Masakazu; Boyle, Frances; Im, Young-Hyuck; Reinisch, Mattea; Molthrop, David; Jiang, Zefei; Wei, Ran; Sapunar, Francisco; Grimes, Brenda R.; Nabinger, Sarah Cassidy; Johnston, Stephen R. D.

• Safety and Clinical Activity of SHR7390 Monotherapy or Combined With Camrelizumab for Advanced Solid Tumor: Results From Two Phase I Trials

  Author: Wei, Xiao-Li; Zhang, Yang; Zhao, Hong-Yun; Fang, Wen-Feng; Luo, Hui-Yan; Qiu, Miao-Zhen; He, Ming-Ming; Zou, Ben-Yan; Xie, Jie; Jin, Chun-Lei; Zhou, Xian-Feng; Wang, Feng; Wang, Feng-Hua; Li, Yu-Hong; Wang, Zhi-Qiang; Xu, Rui-Hua

英文介紹

Oncologist雜志英文介紹

The Oncologist? is dedicated to translating the latest research developments into the best multidimensional care for cancer patients. Thus, The Oncologist is committed to helping physicians excel in this ever-expanding environment through the publication of timely reviews, original studies, and commentaries on important developments. We believe that the practice of oncology requires both an understanding of a range of disciplines encompassing basic science related to cancer, translational research, and clinical practice, but also the socioeconomic and psychosocial factors that determine access to care and quality of life and function following cancer treatment.